Cargando…
Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead
The development of immune checkpoint inhibitors, the monoclonal antibodies that modulate the interaction between immune checkpoint molecules or their ligands on the immune cells or tumor tissue has revolutionized cancer treatment. While there are various studies proving their efficacy in hematologic...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829140/ https://www.ncbi.nlm.nih.gov/pubmed/35155232 http://dx.doi.org/10.3389/fonc.2022.789728 |
_version_ | 1784648005051219968 |
---|---|
author | Aru, Basak Soltani, Mojdeh Pehlivanoglu, Cemil Gürlü, Ege Ganjalikhani-Hakemi, Mazdak Yanikkaya Demirel, Gülderen |
author_facet | Aru, Basak Soltani, Mojdeh Pehlivanoglu, Cemil Gürlü, Ege Ganjalikhani-Hakemi, Mazdak Yanikkaya Demirel, Gülderen |
author_sort | Aru, Basak |
collection | PubMed |
description | The development of immune checkpoint inhibitors, the monoclonal antibodies that modulate the interaction between immune checkpoint molecules or their ligands on the immune cells or tumor tissue has revolutionized cancer treatment. While there are various studies proving their efficacy in hematological malignancies, there is also a body of accumulating evidence indicating that immune checkpoint inhibitors’ clinical benefits are limited in such diseases. In addition, due to their regulatory nature that balances the immune responses, blockade of immune checkpoints may lead to toxic side effects and autoimmune responses, and even primary or acquired resistance mechanisms may restrict their success. Thus, the need for laboratory biomarkers to identify and monitor patient populations who are more likely respond to this type of therapy and the management of side effects seem critical. However, guidelines regarding the use of immune checkpoint inhibitors in hematological cancers and during follow-up are limited while there is no consensus on the laboratory parameters to be investigated for safety and efficacy of the treatment. This review aims to provide an insight into recent information on predictive and prognostic value of biomarkers and laboratory tests for the clinical follow up of hematological malignancies, with an emphasis on leukemia. |
format | Online Article Text |
id | pubmed-8829140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88291402022-02-11 Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead Aru, Basak Soltani, Mojdeh Pehlivanoglu, Cemil Gürlü, Ege Ganjalikhani-Hakemi, Mazdak Yanikkaya Demirel, Gülderen Front Oncol Oncology The development of immune checkpoint inhibitors, the monoclonal antibodies that modulate the interaction between immune checkpoint molecules or their ligands on the immune cells or tumor tissue has revolutionized cancer treatment. While there are various studies proving their efficacy in hematological malignancies, there is also a body of accumulating evidence indicating that immune checkpoint inhibitors’ clinical benefits are limited in such diseases. In addition, due to their regulatory nature that balances the immune responses, blockade of immune checkpoints may lead to toxic side effects and autoimmune responses, and even primary or acquired resistance mechanisms may restrict their success. Thus, the need for laboratory biomarkers to identify and monitor patient populations who are more likely respond to this type of therapy and the management of side effects seem critical. However, guidelines regarding the use of immune checkpoint inhibitors in hematological cancers and during follow-up are limited while there is no consensus on the laboratory parameters to be investigated for safety and efficacy of the treatment. This review aims to provide an insight into recent information on predictive and prognostic value of biomarkers and laboratory tests for the clinical follow up of hematological malignancies, with an emphasis on leukemia. Frontiers Media S.A. 2022-01-27 /pmc/articles/PMC8829140/ /pubmed/35155232 http://dx.doi.org/10.3389/fonc.2022.789728 Text en Copyright © 2022 Aru, Soltani, Pehlivanoglu, Gürlü, Ganjalikhani-Hakemi and Yanikkaya Demirel https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Aru, Basak Soltani, Mojdeh Pehlivanoglu, Cemil Gürlü, Ege Ganjalikhani-Hakemi, Mazdak Yanikkaya Demirel, Gülderen Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead |
title | Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead |
title_full | Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead |
title_fullStr | Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead |
title_full_unstemmed | Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead |
title_short | Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead |
title_sort | comparison of laboratory methods for the clinical follow up of checkpoint blockade therapies in leukemia: current status and challenges ahead |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829140/ https://www.ncbi.nlm.nih.gov/pubmed/35155232 http://dx.doi.org/10.3389/fonc.2022.789728 |
work_keys_str_mv | AT arubasak comparisonoflaboratorymethodsfortheclinicalfollowupofcheckpointblockadetherapiesinleukemiacurrentstatusandchallengesahead AT soltanimojdeh comparisonoflaboratorymethodsfortheclinicalfollowupofcheckpointblockadetherapiesinleukemiacurrentstatusandchallengesahead AT pehlivanoglucemil comparisonoflaboratorymethodsfortheclinicalfollowupofcheckpointblockadetherapiesinleukemiacurrentstatusandchallengesahead AT gurluege comparisonoflaboratorymethodsfortheclinicalfollowupofcheckpointblockadetherapiesinleukemiacurrentstatusandchallengesahead AT ganjalikhanihakemimazdak comparisonoflaboratorymethodsfortheclinicalfollowupofcheckpointblockadetherapiesinleukemiacurrentstatusandchallengesahead AT yanikkayademirelgulderen comparisonoflaboratorymethodsfortheclinicalfollowupofcheckpointblockadetherapiesinleukemiacurrentstatusandchallengesahead |